CAMBRIDGE, Mass., Nov. 13, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals, Inc., today announced that it has named Ian Sanderson its chief financial officer. Mr. Sanderson brings to Catabasis more than 25 years of experience in life sciences investment research and financial operations.
Prior to joining Catabasis, Mr. Sanderson was a senior adviser at JSB-Partners, L.P., a global life sciences advisory firm specializing in strategic partnering and M&A transactions. Prior to JSB-Partners, Mr. Sanderson was a managing director at Cowen and Company, LLC, where he spent 20 years as an equity research analyst covering the specialty pharmaceuticals, pharmaceuticals and medical technology sectors. Mr. Sanderson began his life sciences career in healthcare investment banking at Cowen and Company and at Houlihan Lokey Howard and Zukin, and in financial operations at U.S. Surgical Corporation (now Covidien). Mr. Sanderson also served as a director of development-stage, drug delivery technology company Spherics, Inc., advising on strategic and product development.
"Ian's decades of experience as an advisor and financial analyst and his extensive network of relationships in the life sciences financial community make him an excellent addition to the Catabasis team as the company progresses toward important milestones such as top-line Phase 2 data for our lead compound, CAT-2003," said Jill Milne, Ph.D., co-founder and chief executive officer of Catabasis.
Mr. Sanderson holds a bachelor's degree in political economics from Williams College and an MBA in finance from the University of Pennsylvania.
Catabasis is a clinical-stage company dedicated to the discovery and development of innovative medicines to treat inflammatory and metabolic diseases. The company's drug development programs are rooted in the principles of pathway pharmacology, the treatment of diseases by simultaneously modulating more than one target in a disease pathway. Using its proprietary SMART Linker technology, the company conjugates two drugs that act on different components of a disease pathway with the goal of producing new chemical entities with significantly enhanced efficacy and improved safety and tolerability profiles. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. The company was founded in 2008 and is headquartered in Cambridge, Mass.
Please visit www.catabasis.com for more information.
SOURCE Catabasis Pharmaceuticals, Inc.